{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-029006","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.563814+00:00","generated_at":"2026-06-18T11:16:24.028600+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cara Therapeutics Q4 2022 revenue $3.3M, net loss $30.3M; FY22 revenue $41.9M","bullets":["Q4 2022 total revenue $3.3M (incl. $1.1M collaborative revenue from KORSUVA profit share); FY22 total revenue $41.9M.","Q4 2022 net loss $30.3M ($0.56 per share); FY22 net loss $85.5M ($1.59 per share).","Cash and equivalents $156.7M at Dec 31, 2022; expects to fund operations into first half of 2024.","KORSUVA injection net sales $2.3M in Q4, $35.3M for FY22; wholesaler shipments 20,844 vials in Q4, 207,096 for FY22.","Phase 2/3 program of oral difelikefalin for NP initiated; PMDA decision in Japan expected H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-029006","json":"https://secwatch.observer/filing/0001104659-23-029006.json","markdown":"https://secwatch.observer/filing/0001104659-23-029006.md","text":"https://secwatch.observer/filing/0001104659-23-029006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465923029006/0001104659-23-029006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465923029006/tm238541d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:16:24.028600+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9fd212675bea0458d7c2ef1beddb396774a07be8","claim":"Tvardi Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.","evidence_excerpt":"On March 6, 2023, Cara Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1346830/000110465923029006/0001104659-23-029006-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}